Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614000556640
Ethics application status
Approved
Date submitted
20/05/2014
Date registered
23/05/2014
Date last updated
3/08/2016
Type of registration
Prospectively registered
Titles & IDs
Public title
PILOT study - Recruitment: for a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use in infancy
Query!
Scientific title
A pilot study to determine the likelihood of parents/guardians enrolling their infant into a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use until the age of three at which time they will be assessed for wheeze and atopy.
Query!
Secondary ID [1]
284628
0
None
Query!
Universal Trial Number (UTN)
U1111-1157-0375
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
291943
0
Query!
Eczema
291944
0
Query!
rhinoconjunctivitis
291945
0
Query!
Condition category
Condition code
Respiratory
292296
292296
0
0
Query!
Asthma
Query!
Inflammatory and Immune System
292309
292309
0
0
Query!
Allergies
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Pregnant mothers attending ante-natal classes at Wellington Regional Hospital, and mothers / parents / guardians and infants either in the post-natal wards, or at the immunisation / 6-week check at their primary health care providers will be approached and given an information sheet about the proposed main RCT. After informed consent, they will be asked to fill out a questionnaire.
The questionnaire will be structured in two parts:
Part 1 – demographics of parents, the infant and family history of asthma, eczema and atopy
Part 2 – the likelihood of parents / guardians enrolling their infant into the proposed main trial of paracetamol as required for pain and fever versus ibuprofen, with an assessment of wheeze and atopy at three years of age.
In the proposed main RCT infants will be randomised to receive weight-based doses of ibuprofen up to 4 times a day or weight-based doses of paracetamol up to 4 times a day, as required for pain or fever, from the age of enrolment up until 3 years of age
Query!
Intervention code [1]
289414
0
Not applicable
Query!
Comparator / control treatment
Not applicable
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
292162
0
Proportion of infants where parents / guardians have indicated they would be likely to enrol them in the proposed main trial
Parents will be asked to indicate how likely they woudl be to enrole their infant into the proposed main RCT for a period fo three years on a 5 point scale ranging from 1 'very likely' to 5 'very unlikely'.
Where they have indicated that they would be very unlikely or unlikely they will be given free-form space to indicate their reason why.
Additionally they will be asked to indicate how they would feel about the following aspects of the trial on a 4-point scale: convenience, study length, their infant's health
Query!
Assessment method [1]
292162
0
Query!
Timepoint [1]
292162
0
February 2015
Query!
Secondary outcome [1]
308332
0
Proportion of infants whose mother has current asthma where parents / guardians have indicated they would be likely enrol them in the proposed main trial
Query!
Assessment method [1]
308332
0
Query!
Timepoint [1]
308332
0
February 2015
Query!
Secondary outcome [2]
308333
0
Proportion of infants with a first degree family member (mother, father or sibling) with current asthma where parents / guardians have indicated they would be likely to enrol them in the proposed main trial
Query!
Assessment method [2]
308333
0
Query!
Timepoint [2]
308333
0
February 2015
Query!
Eligibility
Key inclusion criteria
1. Pregnant mothers attending ante-natal classes at Wellington Regional Hospital over a three-week period – specific dates to be arranged
2. Mothers / parents / guardians and infants on post-natal wards at Wellington Regional Hospital over a three week period – specific dates to be arranged
3. Mothers / parents / guardians and infants attending immunisation and 6-week checks at primary health care providers over a three-week period – primary health care providers and specific dates to be arranged
Query!
Minimum age
No limit
Query!
Query!
Maximum age
6
Weeks
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Unable to give informed consent for study
Query!
Study design
Purpose
Screening
Query!
Duration
Cross-sectional
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Sample size and Study Power: As this is pilot study, results of this study will help inform sample size and power calculations of the main proposed trial
Statistical methods. Sample proportions for each of the three recruitment domains will be calculated as follows:
1. Proportion of all infants where parents / guardians have indicated they would be likely to enrol them in the proposed main trial
2. Proportion of infants whose mother has current asthma where parents / guardians have indicated they would be likely to enrol them in the proposed main trial
3. Proportion of infants with a first degree family member with current asthma where parents / guardians have indicated they would be likely to enrol them in the proposed main trial
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
17/11/2014
Query!
Actual
17/11/2014
Query!
Date of last participant enrolment
Anticipated
30/01/2015
Query!
Actual
30/01/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
30/01/2015
Query!
Sample size
Target
150
Query!
Accrual to date
Query!
Final
215
Query!
Recruitment outside Australia
Country [1]
6061
0
New Zealand
Query!
State/province [1]
6061
0
Wellington
Query!
Funding & Sponsors
Funding source category [1]
289257
0
Charities/Societies/Foundations
Query!
Name [1]
289257
0
Medical Research Institute of New Zealand
Query!
Address [1]
289257
0
Level 7, CSB Building, Wellington Hospital, Riddiford Street, Newtown, Wellington 6021
Query!
Country [1]
289257
0
New Zealand
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
Medical Research Institute of New Zealand
Query!
Address
Level 7, CSB Building, Wellington Hospital, Riddiford Street, Newtown, Wellington 6021
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
287932
0
None
Query!
Name [1]
287932
0
Query!
Address [1]
287932
0
Query!
Country [1]
287932
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
291029
0
HDEC New Zealand
Query!
Ethics committee address [1]
291029
0
Query!
Ethics committee country [1]
291029
0
New Zealand
Query!
Date submitted for ethics approval [1]
291029
0
30/05/2014
Query!
Approval date [1]
291029
0
03/07/2014
Query!
Ethics approval number [1]
291029
0
Query!
Summary
Brief summary
The worldwide prevalence of asthma has increased in the past fifty years and there are large differences in prevalence in different countries. The reasons for this are unknown. Better understanding is very important for New Zealand which has one of the highest prevalence rates of asthma and severe asthma in children and adults in the world. There is now substantial observational evidence that paracetamol use may represent a novel risk factor both for the development of asthma and increasing its severity once established. Initially we proposed a randomised open-label parallel group trial of whether paracetamol use, as required for fever and pain, in infants following admission to hospital for bronchiolitis, increased the risk of wheeze and atopy at age 3 compared to placebo. Because paracetamol is so widely used by parents for children for a variety of indications it was difficult to know if parents/guardians will give consent to participate in a study with a 50% chance of randomisation to placebo. We did a feasibility study to determine possible comparators out of ibuprofen, restricted paracetamol (administering paracetamol only if the temperature was greater than 38.5 degrees and / or if the infant was in significant discomfort as recommended by WHO), or placebo. Of 120 infants in our feasibility study we found that Ibuprofen, restricted paracetamol and placebo were acceptable to 42 (58%), 29 (40%) and 9 (12%) parents/guardians respectively. The feasibility raised the question of recruitment sources. We initially wanted to recruit from infants admitted with bronchiolitis. But we only enrolled 36 infants into a ‘mini-RCT’ comparing paracetamol use with restricted paracetamol use in our feaibility study. In the proposed main trial we aim to recruit 1028 participants from 3 main centres. The low recruitment rate seen in our feasibility study would mean we would require a larger number of centres and many years of recruitment to meet our target of 1028 participants. Furthermore, the findings of the study would also only be directly applicable to infants admitted with bronchiolitis and not to all infants who may receive paracetamol Therefore we now wish to explore the possible recruitment rates of all infants, and as a subset, infants whose first degree relatives have asthma, from three possible domains: 1. At ante-natal classes 2. On the post-natal wards 3. At the 6 week immunization visit at the primary healthcare providers
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
A manuscript for this trial has been submitted and is currently under review with NZMJ
Query!
Attachments [1]
55
55
0
0
/AnzctrAttachments/366369-Par-asthma protocol.pdf
Query!
Query!
Contacts
Principal investigator
Name
48534
0
Dr Irene Braithwaite
Query!
Address
48534
0
Medical Research Institute of New Zealand
Private Bag 7902
Wellington 6242
Query!
Country
48534
0
New Zealand
Query!
Phone
48534
0
+64 4 805 0245
Query!
Fax
48534
0
Query!
Email
48534
0
[email protected]
Query!
Contact person for public queries
Name
48535
0
Irene Braithwaite
Query!
Address
48535
0
Medical Research Institute of New Zealand
Private Bag 7902
Wellington 6242
Query!
Country
48535
0
New Zealand
Query!
Phone
48535
0
+64 4 805 0245
Query!
Fax
48535
0
Query!
Email
48535
0
[email protected]
Query!
Contact person for scientific queries
Name
48536
0
Irene Braithwaite
Query!
Address
48536
0
Medical Research Institute of New Zealand
Private Bag 7902
Wellington 6242
Query!
Country
48536
0
New Zealand
Query!
Phone
48536
0
+64 4 805 0245
Query!
Fax
48536
0
Query!
Email
48536
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF